1. Home
  2. SEMR vs SNDX Comparison

SEMR vs SNDX Comparison

Compare SEMR & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SEMR
  • SNDX
  • Stock Information
  • Founded
  • SEMR 2008
  • SNDX 2005
  • Country
  • SEMR United States
  • SNDX United States
  • Employees
  • SEMR N/A
  • SNDX N/A
  • Industry
  • SEMR EDP Services
  • SNDX Biotechnology: Pharmaceutical Preparations
  • Sector
  • SEMR Technology
  • SNDX Health Care
  • Exchange
  • SEMR Nasdaq
  • SNDX Nasdaq
  • Market Cap
  • SEMR 1.1B
  • SNDX 1.1B
  • IPO Year
  • SEMR 2021
  • SNDX 2016
  • Fundamental
  • Price
  • SEMR $7.41
  • SNDX $15.55
  • Analyst Decision
  • SEMR Buy
  • SNDX Strong Buy
  • Analyst Count
  • SEMR 8
  • SNDX 10
  • Target Price
  • SEMR $14.88
  • SNDX $38.40
  • AVG Volume (30 Days)
  • SEMR 1.2M
  • SNDX 2.1M
  • Earning Date
  • SEMR 11-06-2025
  • SNDX 11-04-2025
  • Dividend Yield
  • SEMR N/A
  • SNDX N/A
  • EPS Growth
  • SEMR N/A
  • SNDX N/A
  • EPS
  • SEMR N/A
  • SNDX N/A
  • Revenue
  • SEMR $413,962,000.00
  • SNDX $77,933,000.00
  • Revenue This Year
  • SEMR $20.28
  • SNDX $585.73
  • Revenue Next Year
  • SEMR $16.41
  • SNDX $94.17
  • P/E Ratio
  • SEMR N/A
  • SNDX N/A
  • Revenue Growth
  • SEMR 22.16
  • SNDX 2126.66
  • 52 Week Low
  • SEMR $7.01
  • SNDX $8.58
  • 52 Week High
  • SEMR $18.74
  • SNDX $22.50
  • Technical
  • Relative Strength Index (RSI)
  • SEMR 40.42
  • SNDX 55.19
  • Support Level
  • SEMR $7.32
  • SNDX $15.71
  • Resistance Level
  • SEMR $7.90
  • SNDX $16.65
  • Average True Range (ATR)
  • SEMR 0.23
  • SNDX 0.83
  • MACD
  • SEMR 0.02
  • SNDX -0.25
  • Stochastic Oscillator
  • SEMR 11.92
  • SNDX 13.29

About SEMR SEMrush Holdings Inc.

SEMrush Holdings Inc is engaged in the online visibility management software-as-a-service (SaaS) platform. Its platform utilizes data and intelligence at the core surrounded by AI-powered interconnected hubs focused on search engine optimization, paid advertising, social media management, local marketing, brand marketing, and content marketing Geographically, it generates revenues from the United States, the UK, and Others.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: